Logo

ATXI

Avenue Therapeutics, Inc.

ATXI

Avenue Therapeutics, Inc. • NASDAQ
$0.76 ▼ -12.01% (-0.10)
Market Cap $2.43 M
52w High $2.23
52w Low $0.17
Dividend Yield 0%
P/E 0.99
Volume 206
Outstanding Shares 3.18M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 ▼ $724K ▼ $-683K ▼ 0% ▼ $-0.21 ▼ $-683K ▼
Q2-2025 $1.404M ▲ $1.107M ▼ $335K ▲ 23.86% ▲ $0.11 ▲ $297K ▲
Q1-2025 $0 $1.905M ▲ $-1.852M ▼ 0% $-0.62 ▼ $-1.905M ▼
Q4-2024 $0 $1.596M ▼ $-1.544M ▲ 0% $4.54 ▲ $-1.559M ▲
Q3-2024 $0 $3.156M $-3.076M 0% $-1.92 $-3.018M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $3.709M ▲ $3.725M ▼ $1.422M ▲ $3.557M ▼
Q2-2025 $3.326M ▼ $4.161M ▲ $1.329M ▲ $4.058M ▲
Q1-2025 $3.502M ▲ $3.594M ▲ $1.262M ▲ $3.51M ▲
Q4-2024 $2.594M ▼ $2.672M ▲ $816K ▼ $2.797M ▲
Q3-2024 $2.597M $2.625M $973K $2.61M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-698K ▼ $383K ▲ $0 $0 $383K ▲ $383K ▲
Q2-2025 $329K ▲ $-176K ▲ $0 $0 ▼ $-176K ▼ $-176K ▲
Q1-2025 $-1.858M ▼ $-1.186M ▼ $0 $2.094M ▲ $908K ▲ $-1.186M ▼
Q4-2024 $-1.559M ▲ $-764K ▲ $0 $761K ▲ $-3K ▲ $-764K ▲
Q3-2024 $-3.087M $-2.889M $0 $567K $-2.322M $-2.889M

Five-Year Company Overview

Income Statement

Income Statement Avenue is a classic early‑stage biotech: it has not generated product revenue over the past several years and continues to report operating and net losses. The absolute size of those losses appears modest, reflecting a very lean operation rather than a commercial business. Reported per‑share figures look extremely volatile, but that mainly reflects reverse stock splits and share count changes, not big swings in the underlying business. Overall, the income statement shows a company still firmly in the development phase, spending on operations and R&D without any offsetting sales yet.

Balance Sheet

Balance Sheet The balance sheet data suggest Avenue is operating with very limited assets and cash, essentially a stripped‑down structure typical of a small development‑stage biotech. There is no meaningful reported debt, which removes interest‑burden risk but also points to a reliance on equity or future financings. Equity levels look minimal, implying a thin capital cushion and high sensitivity to any funding delays or cost overruns. In simple terms, the company appears financially fragile and heavily dependent on external capital to keep its programs moving.

Cash Flow

Cash Flow Cash flow patterns are consistent with a pre‑revenue biotech: cash is flowing out from operations to cover overhead and development expenses, with no inflows from product sales and essentially no spending on physical assets. Free cash flow is negative, reflecting ongoing burn, although on a relatively small scale based on the reported figures. The key takeaway is that Avenue consumes cash and will likely need periodic capital raises or partnerships to sustain clinical trials and corporate activities.

Competitive Edge

Competitive Edge Avenue’s competitive position rests on a focused but narrow pipeline in neurology and acute care, rather than on scale or commercial reach. IV tramadol targets a crowded post‑operative pain market dominated by established opioids and non‑opioid options, so success there would depend on clearly demonstrating better safety and practical advantages to win over hospitals and physicians. AJ201 and BAER‑101 sit in more specialized neurological niches, where differentiated mechanisms and potential safety benefits could offer a clearer path to standing out. The company is building a patent estate and is targeting areas with meaningful unmet need, especially SBMA, which can create a degree of protection if the drugs succeed. However, Avenue is small, capital‑constrained, and faces competition from larger pharma and numerous other CNS and pain programs, so its competitive strength will largely hinge on clinical data quality and its ability to secure partners or funding.

Innovation and R&D

Innovation and R&D Innovation is the core of Avenue’s story. Its three main assets each have a distinct scientific angle: an IV form of tramadol aiming to offer opioid‑like pain relief with a more favorable safety and abuse profile; AJ201 as a first‑in‑class candidate for a rare neuromuscular disease with no approved treatments; and BAER‑101 as a more selective modulator of brain receptors designed to reduce seizures or anxiety with fewer sedative and cognitive side effects. The company has in‑licensed assets with prior development history, which partially de‑risks safety for some programs, and is advancing them through mid‑stage trials where upcoming data readouts are crucial. At the same time, progress is highly dependent on access to capital: even strong scientific concepts can stall if the company cannot fund larger, later‑stage studies and regulatory work.

Summary

Overall, Avenue Therapeutics is an early‑stage biotech with no commercial revenue, a very lean and fragile balance sheet, and ongoing cash burn tied to its development pipeline. The investment case is almost entirely about future potential rather than current financial strength. Its value is concentrated in three neurologic and pain‑related drug candidates that aim to combine differentiated mechanisms with meaningful unmet medical needs, supported by patent protection and, in some cases, orphan‑type dynamics. The main opportunities lie in positive clinical trial outcomes, regulatory progress, and potential partnerships, while the key risks are clinical failure, intense competition in pain and CNS markets, and the company’s dependence on fresh financing to continue operations and bring any successful drugs to market.

NEWS

November 6, 2025 · 7:00 AM UTC

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

Read more